Evaluating the potential of 188re-ecd/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment

Tsai Yueh Luo, Ying Hsia Shih, Chiung Yu Chen, I. Chung Tang, Yu Long Wu, Hong Chang Kung, Wuu Jyh Lin, Xi Zhang Lin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Objectives: Intratumoral injection of a radiopharmaceutical is a potential modality to treat liver tumors. Rhenium-188 (188Re) was used to chelate with ethyl cysteinate dimer (ECD) in lipiodol solution to form 188Re-ECD/lipiodol, which was then evaluated for its therapeutic potential in a rodent hepatoma model. Materials and Methods: Male Sprague-Dawley rats were implanted with N1-S1 hepatoma cells orthotopically and randomly divided into two groups. Group 1 (=29) and group 2 (=10) received 188Re-ECD/lipiodol (30.4 > ±21.8MBq/0.1mL) and 0.1 mL of normal saline by intratumoral injection, respectively. Three rats in group 1 were imaged by micro-single-photon emission computed tomography/computed tomography scan to evaluate the biodistribution pattern. All rats were monitored for change of tumor size and survival rate after 2 months. Results: The in vitro stability test showed that 188Re-ECD was well-retained in the lipiodol phase for 48 hours. The biodistribution image revealed that radioactivity was retained well in hepatomas 24 hours postinjection. Long-term studies demonstrated that rats treated with 188Re-ECD/Lipiodol had smaller tumor volumes and a better survival rate, compared to the control group. At the end of observation, the survival rates in groups 1 and 2 were 62% and 20%, respectively (p<0.05). Conclusions: 188Re-ECD/lipiodol via direct intratumoral injection shows potential for treating hepatoma and warrants further clinical trials.

Original languageEnglish
Pages (from-to)535-541
Number of pages7
JournalCancer Biotherapy and Radiopharmaceuticals
Volume24
Issue number5
DOIs
Publication statusPublished - 2009 Oct 1

Fingerprint

Ethiodized Oil
Radiopharmaceuticals
Hepatocellular Carcinoma
Injections
Therapeutics
Rhenium
Tumor Burden
Radioactivity
Sprague Dawley Rats
ethyl cysteinate dimer
Rodentia
Neoplasms
Observation
Clinical Trials
Control Groups
Liver

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

Cite this

Luo, Tsai Yueh ; Shih, Ying Hsia ; Chen, Chiung Yu ; Tang, I. Chung ; Wu, Yu Long ; Kung, Hong Chang ; Lin, Wuu Jyh ; Lin, Xi Zhang. / Evaluating the potential of 188re-ecd/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment. In: Cancer Biotherapy and Radiopharmaceuticals. 2009 ; Vol. 24, No. 5. pp. 535-541.
@article{1186f81ed46a4c5eaa0b2f508b796701,
title = "Evaluating the potential of 188re-ecd/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment",
abstract = "Background/Objectives: Intratumoral injection of a radiopharmaceutical is a potential modality to treat liver tumors. Rhenium-188 (188Re) was used to chelate with ethyl cysteinate dimer (ECD) in lipiodol solution to form 188Re-ECD/lipiodol, which was then evaluated for its therapeutic potential in a rodent hepatoma model. Materials and Methods: Male Sprague-Dawley rats were implanted with N1-S1 hepatoma cells orthotopically and randomly divided into two groups. Group 1 (=29) and group 2 (=10) received 188Re-ECD/lipiodol (30.4 > ±21.8MBq/0.1mL) and 0.1 mL of normal saline by intratumoral injection, respectively. Three rats in group 1 were imaged by micro-single-photon emission computed tomography/computed tomography scan to evaluate the biodistribution pattern. All rats were monitored for change of tumor size and survival rate after 2 months. Results: The in vitro stability test showed that 188Re-ECD was well-retained in the lipiodol phase for 48 hours. The biodistribution image revealed that radioactivity was retained well in hepatomas 24 hours postinjection. Long-term studies demonstrated that rats treated with 188Re-ECD/Lipiodol had smaller tumor volumes and a better survival rate, compared to the control group. At the end of observation, the survival rates in groups 1 and 2 were 62{\%} and 20{\%}, respectively (p<0.05). Conclusions: 188Re-ECD/lipiodol via direct intratumoral injection shows potential for treating hepatoma and warrants further clinical trials.",
author = "Luo, {Tsai Yueh} and Shih, {Ying Hsia} and Chen, {Chiung Yu} and Tang, {I. Chung} and Wu, {Yu Long} and Kung, {Hong Chang} and Lin, {Wuu Jyh} and Lin, {Xi Zhang}",
year = "2009",
month = "10",
day = "1",
doi = "10.1089/cbr.2008.0603",
language = "English",
volume = "24",
pages = "535--541",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

Evaluating the potential of 188re-ecd/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment. / Luo, Tsai Yueh; Shih, Ying Hsia; Chen, Chiung Yu; Tang, I. Chung; Wu, Yu Long; Kung, Hong Chang; Lin, Wuu Jyh; Lin, Xi Zhang.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 24, No. 5, 01.10.2009, p. 535-541.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluating the potential of 188re-ecd/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment

AU - Luo, Tsai Yueh

AU - Shih, Ying Hsia

AU - Chen, Chiung Yu

AU - Tang, I. Chung

AU - Wu, Yu Long

AU - Kung, Hong Chang

AU - Lin, Wuu Jyh

AU - Lin, Xi Zhang

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Background/Objectives: Intratumoral injection of a radiopharmaceutical is a potential modality to treat liver tumors. Rhenium-188 (188Re) was used to chelate with ethyl cysteinate dimer (ECD) in lipiodol solution to form 188Re-ECD/lipiodol, which was then evaluated for its therapeutic potential in a rodent hepatoma model. Materials and Methods: Male Sprague-Dawley rats were implanted with N1-S1 hepatoma cells orthotopically and randomly divided into two groups. Group 1 (=29) and group 2 (=10) received 188Re-ECD/lipiodol (30.4 > ±21.8MBq/0.1mL) and 0.1 mL of normal saline by intratumoral injection, respectively. Three rats in group 1 were imaged by micro-single-photon emission computed tomography/computed tomography scan to evaluate the biodistribution pattern. All rats were monitored for change of tumor size and survival rate after 2 months. Results: The in vitro stability test showed that 188Re-ECD was well-retained in the lipiodol phase for 48 hours. The biodistribution image revealed that radioactivity was retained well in hepatomas 24 hours postinjection. Long-term studies demonstrated that rats treated with 188Re-ECD/Lipiodol had smaller tumor volumes and a better survival rate, compared to the control group. At the end of observation, the survival rates in groups 1 and 2 were 62% and 20%, respectively (p<0.05). Conclusions: 188Re-ECD/lipiodol via direct intratumoral injection shows potential for treating hepatoma and warrants further clinical trials.

AB - Background/Objectives: Intratumoral injection of a radiopharmaceutical is a potential modality to treat liver tumors. Rhenium-188 (188Re) was used to chelate with ethyl cysteinate dimer (ECD) in lipiodol solution to form 188Re-ECD/lipiodol, which was then evaluated for its therapeutic potential in a rodent hepatoma model. Materials and Methods: Male Sprague-Dawley rats were implanted with N1-S1 hepatoma cells orthotopically and randomly divided into two groups. Group 1 (=29) and group 2 (=10) received 188Re-ECD/lipiodol (30.4 > ±21.8MBq/0.1mL) and 0.1 mL of normal saline by intratumoral injection, respectively. Three rats in group 1 were imaged by micro-single-photon emission computed tomography/computed tomography scan to evaluate the biodistribution pattern. All rats were monitored for change of tumor size and survival rate after 2 months. Results: The in vitro stability test showed that 188Re-ECD was well-retained in the lipiodol phase for 48 hours. The biodistribution image revealed that radioactivity was retained well in hepatomas 24 hours postinjection. Long-term studies demonstrated that rats treated with 188Re-ECD/Lipiodol had smaller tumor volumes and a better survival rate, compared to the control group. At the end of observation, the survival rates in groups 1 and 2 were 62% and 20%, respectively (p<0.05). Conclusions: 188Re-ECD/lipiodol via direct intratumoral injection shows potential for treating hepatoma and warrants further clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=70449086486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449086486&partnerID=8YFLogxK

U2 - 10.1089/cbr.2008.0603

DO - 10.1089/cbr.2008.0603

M3 - Article

C2 - 19877883

AN - SCOPUS:70449086486

VL - 24

SP - 535

EP - 541

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 5

ER -